phase2 · 2025
MSC in autoimmune disease: research overview
The most advanced research is in graft-versus-host disease, lupus nephritis and fistulising Crohn's disease. Where products are approved, indications are very narrow.
ClinicalTrials.govTreatment example
Care journey example: rheumatoid arthritis
The sequence for people with rheumatoid arthritis who want to know where stem cell research fits in their care plan.
In short
DMARDs and biologics with strong evidence remain the mainstay. Stem cell studies target immune modulation in people responding poorly and remain investigational.
Step by step
Timings are a general example and may change with documents and clinical judgement.
- 01
Send your question and basic information
Day 1Complete the information-consultation form with your symptoms, how long you have had them, current medicines and previous treatments. The EHL Thailand information team replies in your dashboard. This step is educational information, not a diagnosis.
Who is involved: You + EHL Thailand information team
- 02
Collect your medical documents
Week 1–2Prepare discharge/treatment summaries, blood results, X-ray or MRI images and your medicine list. The more complete the records, the more accurate the eligibility review. Documents are used only with your consent (PDPA).
Who is involved: You + your current treating doctor
- 03
Review the research evidence together
Week 2The team compares MSC research in autoimmune disease with EHL BIO's RASTEM Inj. pipeline entry, and states plainly how much of its study status is public.
Who is involved: Information team + content review panel
- 04
Clinical eligibility screening
Week 3–4A rheumatologist reviews disease activity (e.g. DAS28), radiographic joint damage, latent infection and current drug response before any investigational option.
Who is involved: The doctor or clinic responsible for care in Korea
- 05
Informed consent before deciding
Before travellingBefore deciding you should receive documents stating that the treatment is investigational and not registered in Thailand, the risks, the alternatives, the full costs, and what is still unknown. No outcome guarantee should ever be given.
Who is involved: You + the treating doctor
- 06
Treatment and follow-up
From treatment day to 12 monthsDisease activity scores, inflammatory markers (ESR/CRP) and joint function are followed at 1, 3, 6 and 12 months.
Who is involved: Treating doctor + your doctor in Thailand
Documents to prepare
- Recent RF, anti-CCP, ESR and CRP results
- Hand and foot radiographs
- History of DMARDs and biologics already used
- Tuberculosis and hepatitis screening results
Questions to ask your doctor
- Which evidence-based drugs have not been used yet?
- Could an investigational treatment disturb current disease control?
- How much does infection risk increase?
- Which measures will judge whether it worked?
Limits you must know
- Stem cell treatment for these conditions remains investigational; it is not standard care.
- EHL Thailand is an information and consultation channel, not a clinic, and does not diagnose or prescribe.
- EHL BIO pipeline cell products have no published Thai registration status.
- The timings shown are a general example and may change with documents, extra tests and clinical judgement.
Related disease page
Rheumatoid Arthritis
An autoimmune disease causing chronic synovial inflammation and joint damage.
Research cited in this journey
review · 2026
EHL BIO GMP cell manufacturing centre
Company public information describes the manufacturing centre, quality systems and cell handling processes. Certifications and current status should be verified at the source.
EHL BIO — GMP centerpreclinical · 2024
RASTEM Inj.: preclinical study in rheumatoid arthritis (hospital information)
The hospital's affiliated research centre states the non-clinical study is being completed and a clinical trial is in preparation. No human outcome data exist; patients should follow standard care such as methotrexate and biologics as prescribed.
EHL BIO (research page)Experts involved
Profiles show only details checkable against public sources.
EHL BIO Immune Cell Research Team
Immune cell therapy research and immune cell banking
Keycell-IM programme (T, NK, iNKT and dendritic cells); the hospital's affiliated research centre states lung cancer as the preclinical target
EHL BIO — Immune Cell TherapeuticsEHL Thailand Research Desk
Reviews articles, research summaries and clinical trial status
Careful reading of study results, including sample size, trial phase and limitations
Experts behind this content
EHL Thailand Research Desk — Careful reading of study results, including sample size, trial phase and limitations
EHL BIO scientific information is compiled alongside public information from its research team and GMP centre. See the full expert panel
Frequently asked questions
Last updated 3 Sept 2026